• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.ZAP70激活通过JAK-STAT3信号通路的激活来补偿IA类PI3K亚型的缺失。
Cancer Diagn Progn. 2022 May 3;2(3):391-404. doi: 10.21873/cdp.10122. eCollection 2022 May-Jun.
2
Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.IA 类磷酸肌醇 3-激酶同工型 p110α 介导血管重塑。
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1434-44. doi: 10.1161/ATVBAHA.114.304887. Epub 2015 Apr 23.
3
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.任何一类 IA 型 PI3K 同工酶的活性都能维持细胞的增殖和存活。
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11381-6. doi: 10.1073/pnas.0906461107. Epub 2010 Jun 7.
4
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.肿瘤形成对磷脂酰肌醇3激酶(PI3K)亚型的依赖性取决于PI3K途径激活的遗传模式,而非组织类型。
J Virol. 2014 Sep;88(18):10673-9. doi: 10.1128/JVI.01409-14. Epub 2014 Jul 2.
5
Dynamics of GFP-Fusion p110α and p110β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.PI3K信号通路中GFP融合的p110α和p110β亚型在正常细胞和癌细胞中的动力学
J Cell Biochem. 2016 Dec;117(12):2864-2874. doi: 10.1002/jcb.25598. Epub 2016 Jun 3.
6
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.IGF1R/p110β/AKT/mTOR的激活赋予对α特异性PI3K抑制的抗性。
Breast Cancer Res. 2016 Apr 5;18(1):41. doi: 10.1186/s13058-016-0697-1.
7
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER Breast Cancer.在PTEN缺陷型雌激素受体阳性乳腺癌中,持续的治疗效果需要同时抑制磷脂酰肌醇3激酶的p110α和p110β亚型。
Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.
8
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.增强的 PI3K p110α 信号转导赋予获得性拉帕替尼耐药性,而这种耐药性可以被 p110α 选择性 PI3K 抑制剂有效地逆转。
Mol Cancer Ther. 2014 Jan;13(1):60-70. doi: 10.1158/1535-7163.MCT-13-0518. Epub 2013 Nov 18.
9
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.PI3K 的 p110α 和 p110β 同工型都可以调节 PTEN 肿瘤抑制因子失活的影响。
Biochem J. 2012 Feb 15;442(1):151-9. doi: 10.1042/BJ20111741.
10
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.PI3K-p110α介导HER2阳性、PTEN缺失的乳腺癌对HER2靶向治疗的耐药性。
Oncogene. 2016 Jul 7;35(27):3607-12. doi: 10.1038/onc.2015.406. Epub 2015 Oct 26.

引用本文的文献

1
Molecular mechanisms of PI3K isoform dependence in embryonic growth.胚胎发育中PI3K同工型依赖性的分子机制。
J Turk Ger Gynecol Assoc. 2024 Aug 29;25(3):159-166. doi: 10.4274/jtgga.galenos.2024.2024-6-7.
2
Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis.基于网络的磷酸化蛋白质组学时间序列分析揭示结肠癌耐药机制。
Nat Commun. 2024 May 9;15(1):3909. doi: 10.1038/s41467-024-47957-3.
3
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.细胞柔软度使细胞毒性 T 淋巴细胞和 T 白血病细胞对穿孔素介导的杀伤产生抗性。
Nat Commun. 2024 Feb 15;15(1):1405. doi: 10.1038/s41467-024-45750-w.
4
Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.胆固醇生物合成是内分泌治疗耐药性癌症的一个依赖于 PTEN 的可操作节点。
Cancer Sci. 2023 Nov;114(11):4365-4375. doi: 10.1111/cas.15960. Epub 2023 Sep 14.

本文引用的文献

1
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.对整个转录组进行生存分析可识别出乳腺癌中具有最高预后能力的生物标志物。
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109. doi: 10.1016/j.csbj.2021.07.014. eCollection 2021.
2
Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.前列腺腺癌前列腺切除术 3 年后生化复发的微环境相关潜在生物标志物的鉴定。
Aging (Albany NY). 2021 Jun 16;13(12):16024-16042. doi: 10.18632/aging.203121.
3
Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.SYK 和 ZAP70 的发育性分隔可预防自身免疫和癌症。
Mol Cell. 2021 May 20;81(10):2094-2111.e9. doi: 10.1016/j.molcel.2021.03.043. Epub 2021 Apr 19.
4
A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma.一种基于七种免疫相关 RNA 的新型预后预测模型,用于预测早期宫颈鳞状细胞癌患者的总生存率。
BMC Med Genomics. 2021 Feb 15;14(1):49. doi: 10.1186/s12920-021-00885-3.
5
Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy.超越 TCR 信号:Lck 在癌症和免疫疗法中的新兴功能。
Int J Mol Sci. 2019 Jul 16;20(14):3500. doi: 10.3390/ijms20143500.
6
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.PI3K 抑制剂临床开发面临的挑战:提高其在实体瘤中疗效的策略。
Cancer Discov. 2019 Apr;9(4):482-491. doi: 10.1158/2159-8290.CD-18-1175. Epub 2019 Mar 13.
7
Targeting PI3K in cancer: mechanisms and advances in clinical trials.针对癌症的 PI3K 靶向治疗:机制与临床试验进展。
Mol Cancer. 2019 Feb 19;18(1):26. doi: 10.1186/s12943-019-0954-x.
8
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.PIM 激酶诱导的 PI3K 抑制剂治疗耐药的机制。
Mol Cancer Ther. 2018 Dec;17(12):2710-2721. doi: 10.1158/1535-7163.MCT-18-0374. Epub 2018 Sep 6.
9
Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.非受体酪氨酸激酶在血液系统恶性肿瘤中的作用及其被天然产物靶向。
Mol Cancer. 2018 Feb 19;17(1):31. doi: 10.1186/s12943-018-0788-y.
10
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.PI3Kα 选择性抑制剂 Alpelisib(BYL719)治疗 PI3CA 改变的实体瘤:首例人体研究结果。
J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5.

ZAP70激活通过JAK-STAT3信号通路的激活来补偿IA类PI3K亚型的缺失。

ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.

作者信息

Demir Melike, Cizmecioglu Onur

机构信息

Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.

出版信息

Cancer Diagn Progn. 2022 May 3;2(3):391-404. doi: 10.21873/cdp.10122. eCollection 2022 May-Jun.

DOI:10.21873/cdp.10122
PMID:35530641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9066532/
Abstract

BACKGROUND/AIM: Tyrosine kinases have crucial functions in cell signaling and proliferation. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently deregulated in human cancer and is an essential regulator of cellular proliferation. We aimed to determine which tyrosine kinases contribute to resistance elicited by PI3K silencing and inhibition.

MATERIALS AND METHODS

To mimic catalytic inactivation of p110α/β, specific p110α (BYL719) and p110β (KIN193) inhibitors were used in addition to genetic knock-out in in vitro assays. Cell viability was assessed using crystal violet staining, whereas cellular transformation ability was analyzed by soft-agar growth assays.

RESULTS

Activated zeta chain of T-cell receptor-associated protein kinase 70 (ZAP70) generated resistance to PI3K inhibition. This resistance was via activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) axis. We demonstrated that activated ZAP70 has a high transforming capability associated with the formation of malignant phenotype in untransformed cells and has the potential to be a tumor-initiating factor in cancer cells.

CONCLUSION

ZAP70 may be a potent driver of proliferation and transformation in untransformed cells and is implicated in resistance to PI3K inhibitors in cancer cells.

摘要

背景/目的:酪氨酸激酶在细胞信号传导和增殖中发挥着关键作用。磷脂酰肌醇3-激酶(PI3K)通路在人类癌症中经常失调,是细胞增殖的重要调节因子。我们旨在确定哪些酪氨酸激酶会导致PI3K沉默和抑制所引发的耐药性。

材料与方法

为模拟p110α/β的催化失活,除了在体外实验中进行基因敲除外,还使用了特异性的p110α(BYL719)和p110β(KIN193)抑制剂。使用结晶紫染色评估细胞活力,通过软琼脂生长实验分析细胞转化能力。

结果

T细胞受体相关蛋白激酶70(ZAP70)的活化ζ链产生了对PI3K抑制的耐药性。这种耐药性是通过激活Janus激酶/信号转导和转录激活因子3(JAK/STAT3)轴实现的。我们证明,活化的ZAP70具有高转化能力,与未转化细胞中恶性表型的形成有关,并且有可能成为癌细胞中的肿瘤起始因子。

结论

ZAP70可能是未转化细胞增殖和转化的有效驱动因子,并与癌细胞对PI3K抑制剂的耐药性有关。